Skip to content
Screener

NeoGenomics NEO Q4 2025 Annual earnings

Reported February 17, 2026 · Before market open

Revenue$190.2MBeat by $1.7M
EPS$0.06Beat by $0.02
Revenue estimate$188.5M
EPS estimate$0.04

Next report

Oct 27, 2026 (in a month)
Revenue estimate$205.9M
EPS estimate$0.06

Financials

Q4 2025

Income statement

See full
Revenue$190.2M+10.6%
Gross profit$83.3M+7.9%
Operating income-$13.4M+27.1%
Net income-$9.9M+35.5%
EPS (diluted)-$0.07+41.7%

Balance sheet

See full
Cash & equivalents$159.6M-56.5%
Total debt$409.5M+54.5%
Total equity$836.6M-7.3%
Total assets$1.4B-17.0%

Cash flow

See full
Operating cash flow$1.3M-86.3%
CapEx$7.9M-32.1%
Free cash flow-$6.5M-263%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.52B-28.1%
Enterprise value$1.77B-12.0%
P/S2.1×-1.1×

Profitability

See full
Gross margin43.2%-0.7pp
Operating margin-15.9%+2.7pp
Net margin-14.9%+4.9pp

Returns & leverage

See full
Return on equity-12.4%+10.4pp
Debt / equity0.5×+0.2×
Current ratio4.3×+2.3×

Segments

By product

See full
Client direct billing$133.4M-29.9%
Commercial insurance$31.4M+17.5%
Medicare and other government$25.4M+16.8%

By segment

See full
Reportable Segment$190.2M+10.6%

FAQ

When did NeoGenomics report Q4 2025 earnings?
NeoGenomics (NEO) reported Q4 2025 earnings on February 17, 2026 before market open.
What were NeoGenomics's Q4 2025 revenue and EPS?
NeoGenomics reported revenue of $190.2M and eps of $0.06 for Q4 2025.
Did NeoGenomics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $188.5M by $1.7M. EPS beat the consensus estimate of $0.04 by $0.02.
How did NeoGenomics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.6% from $172.0M a year earlier and eps grew 50.0% from $0.04.
Where can I find NeoGenomics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001077183-26-000004) and the 10-K periodic report (0001077183-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.